Fig. 5From: Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraineFrequency of PGIC responsea according to PGIC rating at Month 1: (A) very much improved, (B) much improved, (C) minimally improved, (D) no improvement. aPGIC response defined as rating of “much improved” or “very much improved.” bIncludes patients reporting “no change,” “minimally worse,” “much worse,” and “very much worse.” Analysis conducted in patients with PGIC data at all time points. PGIC, Patient Global Impression of ChangeBack to article page